	National Colorectal Cancer Roundtable The National Colorectal Cancer Roundtable (NCCRT) is a coalition of organizations dedicated to improving colorectal cancer (CRC) control through promoting communication, collaboration, and coordination among medical professionals, health agencies, and the public. The NCCRT website contains a resource library with a large collection of books, brochures, links, and other types of resources related to CRC, many of which are also available in Spanish. Public awareness and patient education booklets are available, but there are some that provide information for healthcare professional, as well. These include guides on irritable bowel syndrome, gastrointestinal disorders, improving delivery of CRC screening, cleaning and disinfection of endoscopes, and more. Other sections of the website feature a CRC news page, a calendar of events related to CRC, new journal abstracts, and an education and outreach library.

	The Susan Cohan Kasdas Colon Cancer Foundation The Susan Cohan Kasdas Colon Cancer Foundation (CCF) is an organization dedicated to fighting colon cancer by raising public awareness and educating patients. The CCF website has a colon cancer information section with a general summary of the disease and explanations of disease prevention, the stages of colon cancer, flexible sigmoidoscopy, colostomy, colon cleansers, and a treatment option overview. Explanations are accompanied by full-color diagrams to help illustrate them. The CCF website also has informational sections on colon cancer screening, prevention, heredity, clinical trials, and colonoscopies. Another section has more in-depth information on surgery options, and features pages on minimally invasive procedures for colon surgery, colon cancer, and colon polyps; an illustrations and graphics collection; information on post-surgery issues and risks; what to ask one’s physician; other online resources; and a colectomy movie. The CCF also offers a monthly eNewsletter, with archived issues available.

Single sigmoidoscopy could prevent one-third of colorectal cancers

	Credits: 0.25 Fee: None Expires: May 6, 2011 This CME activity is based on a news article about the results of a new study from the United Kingdom published online in The Lancet. The study found that a single examination using flexible sigmoidoscopy in healthy individuals between 55 and 64 years of age, as well as the removal of any found polyps, reduced CRC incidence by one third. It also reduced deaths from the disease by 43%. The study had a median follow- up of 11 years. On completing the activity, participants should be able to evaluate flexible sigmoidoscopy as an option for CRC screening. Participants should also be able to identify long-term outcomes associated with one-time screening using flexible sigmoidoscopy.

Surveillance with serial serum carcinoembryonic levels detect CRC recur- rences in patients who are initial nonsecretors

The American Surgeon Authors: Holt A, Nelson RA, Lai L Purpose: Patients with CRC who present with elevated serum carcino- embryonic antigen (CEA) levels are typically monitored for recurrence after initial resection. It has not been confirmed whether there is any value in following nonsecretors, patients who present with normal or lowered CEA. In order to determine the value of follow-up CEA levels in nonsecretors, the authors of this study performed a retrospective review of patients with resected Stage I, II, and III CRC. Patients who did not have a pretreatment CEA level, at least 2 follow-up CEA levels, and normal- ized CEA levels after resection were excluded for this study.

 186 patients with CRC were included in the study. 146 of them were initial nonsecretors. Of the 22 patients who developed recurrent CRC, 6 were secretors and 16 were nonsecretors. In the secretors group, CEA levels were elevated with recur- rence in 4 of the patients. The CEA levels were elevated in 8 of the non- secretors. The authors concluded that many CRC recurrences are marked by elevated CEA levels, regardless of whether the patients were initially secretors or nonsecretors. 

A clinical study of PHY906 as a modulator of CPT-11 in patients with metastatic CRC

	Study Type: Interventional Age/Sex Requirements: 18 years (None) Sponsor: Yale University ClinicalTrials.gov Identifier: NCT00730158 Purpose: This study will be testing the use of PHY906 in combination with CPT-11 as an adjunct to chemotherapy in the treatment of patients with metastatic CRC. PHY906 is an oral form of a spray-dried aqueous extract made of four primary herbs that have been used in Chinese herbal medicine for almost 2000 years to treat various gastroin- testinal problems, such as diarrhea and nausea/vomiting. Other studies have shown that Chinese herbal medicine demonstrates significant anticancer activity when used in combination with certain cytotoxic agents, including CPT-11. CPT-11 is a semi-synthetic derivative of the natural alkaloid camptothecin and is classified as a topoisomerase I inhibi- tor. The researchers conducting this study believe that the therapeutic use of PHY906 may reduce chemo- therapy-induced toxicity, especially diarrhea, in patients with metastatic CRC. The primary outcome measure of the study will be to determine the maximum tolerated dose of PHY906 when it is combined with a stan- dard dose of CPT-11, as well as the response rate in patients with meta- static CRC. The secondary measures will be progression-free survival and overall survival.

Articles

Useful Online Resources and Clinical Trials for Colon Cancer

Net Guides: Colon Cancer

	“Development of this technology has involved many scientific disciplines beyond oncology: physics, chemistry, biophysics, cellular biology, radiobiology, molecular biology, physical chemistry, and others.”

	Radiation, used to treat more than half of all cancers, can sometimes be as toxic to the body as it is to the tumor. Advances in nanomedicine, however, may soon make it possible for radiation oncologists and technicians to deliver doses of x-rays that are strong enough to destroy the cancer without damaging healthy tissues.

	With a new device from Nanobiotixcalled NanoXray

, inert nanoparticles, between 100 and 1000 times smaller than the diameter of a human hair,are injected into the cancer and activated by a standard x-ray. These nanoparticles, called NBTXR3,absorb high levels of radiation. Once activated, these particles create electrons that, in turn, generate free radicals, which inflict irreversible damage to the cancerous cells and cause their destruction, while the surrounding cells receive a simple standard dose of radiation.

	In early 2011, Nanobiotixplans tobegin clinical trials with NanoXray at the Gustave Roussy Institute, Paris, an international center of excellence in cancer treatment. The chief executive officer of Nanobiotix, Laurent Levy, PhD, has been working with nanotechnologies for more than a decade, developing practical applications, such as NanoXray. Levy is the president of the French Technology Platform ofNanomedicine and author of 35international publications and communications. Here, Levy discusses this new technology.

	NanoXray is a technology in which crystallineand inert nanoparticles are designed to reach the tumor and then are activated by a standard x-ray. Once into the tumor, the nanoparticles accumulate in the cancer cell, and the x-ray activates the particles to release large amounts of energy in the cell.  The electrons produced after the nanoparticles absorb a high level of x-rays generate large quantities of free radicals.

	These free radicals inflict nonspecific,irreversible damage to the cancerous cell that leads to its destruction and multiplies the effects of radiation therapy. Due to their unique design and physical properties, the nanoparticles present in the cancerous tissues absorb a strong dose of x-rays, while healthy tissues receive a standard x-ray dose.

What advantages over standard radiotherapy methods will NanoXray offer?

	There are many potential benefits from this new approach to radiation therapy:First, it achieves a better local tumor control with an inert product. Secondly, it has a good safety profile demonstrated in animal models, and lastly, it delivers a higher dose to achieve total tumor control.

	The product augments efficacy of radiation therapy. Radiation has been effective against cancer for more than 50 years, and nanoparticles emitted by NanoXray have been thoroughly investigated and found to cause no harm in noncancerous cells over long periods of time.

	NanoXray could be combined with existing therapies, such as chemotherapy, surgery, and immunotherapy, and with molecularly targeted drugs. The device provides for “on/off” therapy. The inert nanoparticles  are only rendered active when exposed to radiation. One injection of the nanoparticles should last through a course of several radiation therapy sessions, and the device works with all standard radiotherapy equipment.

	Radiation oncologists and technicians can combine NanoXray with other approaches to improve radiation therapy outcomes, such as more focused imaging techniques and technologies that improve the focus of the radiation beam.

	Nanobiotixhas 3 products in the pipeline. The first (NBTXR3) will enter clinical trials in early 2011. This compound will be injected directly into the tumor.

	A second nanoparticle (NBTXR-IV), currently being investigated in nonclinical studies, may be injected intravenously to treat other cancers where an intravenous injection is the optimum delivery route.

	The third (NBTX TOPO) is being developed for use during surgery, to prepare the cancer site for follow-up radiotherapy, such as in breast cancer surgery. Based on the existing technology and preclinical results, Nanobiotix is developing other nanomedicine programs beyond NanoXray that will sustain its pipeline and expand the uses of nanoparticles in medicine.

Which cancer patients would be more likely to benefit from the NanoXray?

	Given the universal nature of the mode of action of these particles, this technology could be applied to all radiotherapy applications, that is, 50% to 60% of patients with cancer, while maintaining an optimal standard of care. The potential expands beyond this application because the mode of action of the nanoparticle product is not specific and could, in the future,open new routes for radiotherapy.

	Nanobiotix plans to address liver cancer, glioblastoma, rectal cancer, prostate cancer, non-small cell lung cancer, and breast cancer with various formulations of the product.

Describe the evidence supporting your contention that NBTXR3 not only delivers positive outcomes, but also shows superiority over standard therapies? 

	Nonclinical research indicates the treatment is safe, effective, and delivers a dose of radiation that is markedly higher than traditional radiation therapy. Nonclinical and preclinical research is completed, and this research paves the way for clinical trials to begin in Europe in early 2011. Preliminary research with the first NanoXray product (NBTXR3) in several animal models demonstrated a complete tumor regression and prolonged survival.

	Intratumoral injection of NBTXR3 nanoparticles activated via standard radiation therapy led to complete tumor regression and showed survival benefit in mice bearing human cancer cells. The preclinical study showed that an intratumoral injection of NBTXR3 nanoparticles activated via standard radiation therapy led to complete tumor regression in mice at 60 days, and showed significant survival advantages. NanoXray used in combination with radiotherapy should help it to achieve a better local control and should not compete with other products.

Are there adverse effects with NanoXray therapy and, if so, how would they be managed?

	NBTXR3 nanoparticles are designed to be safe and effective treatment for radiosensitive and radioresistant tumors. Two years ago, Nanobiotix commenced a large safety assessment program in animals to acquire knowledge about NBTXR3's biodistribution, excretion, and potential toxicology effects in healthy and tumor-bearing animals.

	Despite the intended use of NBTXR3 as a local injection directly into a tumor, NBTXR3 was tested in animals as a systemic injection into the vein in order to mimic a clinical situation of accidental and massive passage of NBTXR3 nanoparticles into the bloodstream during the procedure of intratumor injection.

	Preclinical tolerance studies in terms of animal survival, behavior, and pathological assessment indicated capture by the reticulo-endothelial system and negligible toxicity, even for dose-maximization situations in which NBTXR3 was injected by intravenous route on 5 consecutive days.

	Results suggested absence of any indolent disease characteristics in male and female animals. Excretion studies following intravenous administration showed identical data for male and female animals, with NBTXR3 very slowly eliminated by feces per plan and no presence of NBTXR3 in urine. For the systemic administrations, NBTXR3 nanoparticles underwent endocytosis mainly in the mononuclear phagocyte system. There was no evidence of blood/brain barrier rupture. Also, no presence of inflammation or degenerative change was found in toxicology study.

What trials are underway or planned? What has been identified as the primary endpoint of these trials?

	In early 2011, Nanobiotix will begin clinical trials with NBTXR3, the first NanoXray product. The trial’s first indication will be on soft tissue sarcomas, a rare form of cancer that develops in different tissues such as in fat, muscle, and others. The primary endpoints of this trial are to demonstrate feasibility and the innocuity of the treatment in humans.

What technological advances made the NanoXray possible?

	The nanoparticle used in NanoXray technology is an inactive and inert substance (not a drug), measuring 50 nanometers in diameter—up to 1000 times smaller than the diameter of a human hair.

	The nanoparticle comprises a crystalline inorganic core and a coating layer that protects the core from unintended biological interactions within the body. Development of this technology has involved many scientific disciplines beyond oncology: physics, chemistry, biophysics, cellular biology, radiobiology, molecular biology, physical chemistry, and others. The ability to design, qualify, and manufacture such nanoparticles have been key factors in the development.

Describe how those advances were used to develop this technique?

	I have worked in the nanotechnology field for 15 years as a scientist, but also as an entrepreneur. I started with my PhD in nanotechnology, where I explored the impact of scale on the physical properties of nanomaterials—in other words, how to design and reduce the size of a material to tune and exploit its new properties.

	After this step, I thought about using the unique properties of nanoparticles to kill cancer cells. I had to go to the US (University at Buffalo, The State University of New York) to find a multidisciplinary team that could explore the concept of how to combine biology, nanomaterial, chemistry, and physics to develop nanomedicine applications. At this time the concept was very new, and everything needed to be done. Later, when we created Nanobiotix, we had to expend our knowledge to take the technology to the next level and make it industrial.

What materials form the nanoparticles used in the NanoXray, and how are the nanoparticles manufactured?

	NanoXray compounds are based on crystalline HfO2 nanoparticles. A specific manufacturing process has been developed that is scalable, ensures batch-to-batch reproducibility, and allows flexible manufacturing of several products. Successive NBTXR3 batches have been successfully validated and qualified. The current process produces sufficient materials for the completion of preclinical development, clinical trials, and potentially, initial commercialization. A manufacturer with GMP [good manufacturing processes] and injectable-product capabilities handles the production.

What stage of the development cycle are you in, and when do you think this product will be ready to submit for FDA and/or EMEA approval? When will it reach the market?

	The NanoXray therapeutics, due to their physical mechanism of action, have been classified as class III medical devices by some of the regulatory authorities in EU countries. The first Nanobiotix product, NBTXR3 for intratumoral injection, is planned to launch around 2014, but of course this always depends on development orientation and timelines, which may vary depending on clinical results.

What major challenges have you and your company faced thus far in developing this technology?

	As any young innovative healthcare company, Nanobiotix went through “classical” steps combining technological development, finding the right financing, executing manufacturing, defining the regulatory pathway, finding the right people, and so on, On top of that, Nanobiotix faces major challenges, as long as it is not a classical biotech player, involved in molecule development: We still have to educate, excite, and endorse to help our target audiences to think out of the box. These are very important tasks since we want this technology to benefit to patient as soon as possible.

Radiation, used to treat more than half of all cancers, can sometimes be as toxic to the body as it is to the tumor.

Nanotechnology X-ray Method Aims to Kill Cancer But Spare Healthy Tissue

Gene Signature Test Predicts Colorectal Cancer Recurrence

	ColoPrint, a microarray-based gene signature test, accurately identifi ed the risk of recurrence of colorectal cancer in patients with localized stage II disease, raising the potential of an exciting new prognostic tool for clinicians.

	Robert Rosenberg, MD, an assistant professor at the University Hospital of the Technical University in Munich, and colleagues used ColoPrint to analyze the expression of 18 genes in tumor tissue from 233 patients who had undergone surgical resection for stage II or III colorectal cancer from 1987 to 2003.

	Of the 135 stage II patients, ColoPrint identifi ed 73% as low risk; only 5% developed recurring cancer within 5 years or more. The test identifi ed the remaining 27% as high risk, and 20% of these patients developed cancer with a median follow-up of 97 months.

	Intensity-modulated radiation therapy (IMRT) in combination with chemotherapy delivered the same results as conventional combination radiation therapy, but with fewer adverse effects in anal cancer patients, according to study results presented by Lisa Kachnic, MD, chair of radiation oncology at Boston University, Massachusetts.

	Kachnic, the principal investigator of the phase II Radiation Therapy Oncology Group (RTOG) trial, said in a press release that IMRT plus 5-fl uorouracil and mitomycin-C chemotherapy was “associated with signifi cant sparing of grade 3 and higher dermatologic and gastrointestinal acute toxicity.”

	In the RTOG 0529 study, 52 stage II and stage III patients were treated with IMRT plus the chemotherapy regimen for 2 years. At median follow-up of 26.7 months, the 2-year disease-free survival (DFS) rate was 77% and overall survival (OS) was 86%. Investigators said the 325-patient RTOG 9811 trial, where patients received conventional radiation, resulted in 75% DFS and 91% OS with greater acute toxicity.

	Positron emission tomography (PET) testing after 2 weeks of chemotherapy and before surgery helped determine whether patients with locally advanced adenocarcinoma of the esophagogastric junction would benefi t from additional radiation, researchers reported.

	The prospective study MUNICON II involved 56 patients who were divided into 2 groups based on their response to initial chemotherapy as measured by PET results. The 33 responders were given an additional 3 months of chemotherapy before surgery, while the 23 nonresponders were given radiation before surgery aimed at shrinking tumor size.

	Of the responders, 27 patients (82%) underwent curative surgery and have not yet reached median event-free survival and median OS after 38 months. Among nonresponders, 16 patients (70%) underwent curative surgery; the median event-free survival and OS were 15.4 months and 18.3 months, respectively.

	The trial outcomes were reported by lead researcher Florian Lordick, MD, PhD, director of the Department of Hematology and Oncology at Klinikum Braunschweig in Brunswick, Germany, and senior lecturer at Hannover Medical School. She said at a press conference that the study is the fi rst attempt to guide treatment based on early PET testing, but that it unfortunately shows the lack of salvage treatment for those without an early response.

ISH Testing Poses Advantages in Evaluating HER2 Expression 

	A comparison of methods for assessing the expression of human epidermal growth factor receptor 2 (HER2) in gastric cancer determined that in-situ hybridization (ISH) yields the best results, Australian researchers reported in a poster presentation.

	The question is an important one since up to 33% of advanced gastric cancer cases exhibit amplifi cation or overexpression of HER2, M. Priyanthi Kumarasinghe, PhD, a clinical pathologist at Queen Elizabeth II Medical Center in Perth, and colleagues noted. Studies have shown that the anti-HER2 monoclonal antibody trastuzumab improves survival in HER2-positive disease, making accurate and consistent testing crucial for the use of HER2 as a predictive marker in gastric cancer, they said.

	And, although HER2 testing in breast cancer has become routine in Australia as part of a national program, pathologists have limited experience in the evaluation of HER2 expression in gastric cancer tissue.

	To assess the status of HER2 testing for this population, Kumarasinghe and colleagues conducted an interlaboratory reproducibility study involving 9 reference laboratories. Each laboratory received a tissue microarray encompassing 100 prescreened samples from patients with gastric or gastroesophageal junction adenocarcinoma. The laboratories evaluated the specimens for HER2 expression by both immunohistochemistry (IHC) and ISH (chromogenic ISH [CISH], silver ISH [SISH], or fl uorescence ISH [FISH]).

	The laboratories demonstrated good concordance for ISH evaluation, the research team reported. In contrast, only moderate agreement emerged from IHC staining, except for IHC3 specimens.

	“The good concordance across laboratories for HER2 copy number . . . suggests that ISH is the optimal method for HER2 testing in gastric cancer,” Kumarasinghe said. “The agreement between laboratories on HER2 score of samples by IHC was moderate, likely due to discordance between laboratories on the assignment of IHC1 and IHC2 samples, suggesting the need for ISH confi rmation in these cases.”

	For all levels of HER2 (IHC0-IHC3 ) expression, the laboratories had overall agreement of 68%. Grouping IHC0/1 together resulted in an overall accuracy of 84%, increasing to 92% when IHC3 was a separate category and the other 3 levels of expression were considered as 1.

	Laboratories using CISH/SISH had good or very good concordance when HER2 expression was defi ned by copy number (κ = 0.81), but agreement declined when test results were defi ned by HER2:chromosome 17 ratio (κ = 0.69). Comparison of central FISH with CISH/SISH showed the best results when results were defi ned by HER2 copy number (κ = 0.90).

	On the basis of their fi ndings, the investigators recommended the following testing algorithm for HER2 expression in gastric cancer:

	• IHC alone is not suffi cient for determining HER2 status in gastric cancer.

	• Use of the HER2/chr17 ratio in ISH should be restricted to equivocal cases.

	• IHC should be used for initial evaluation, followed by single-probe ISH evaluation for specimens that exhibit 

ColoPrint, a microarray-based gene signature test, accurately identifi ed the risk of recurrence of colorectal cancer in patients with localized stage II disease, raising the potential of an exciting new prognostic tool for clinicians.

2011 Gastrointestinal Cancers Symposium

	From tiny biotech firms to giant pharmaceutical companies, the oncology drug development pipeline is pulsing with activity. There are nearly 900 potential new medicines and vaccines to treat cancer under study in the United States, according to the Pharmaceutical Research and Manufacturers Association of America. These include 122 for lung cancer, 107 for breast cancer, 70 for colorectal cancer, and 103 for prostate cancer. Considering the complexity of the clinical trials process, predications about which drugs will gain the FDA’s approval can stymie even the best industry analysts. Here, then, is a look at 7 oncology drugs that you’ll hear about this year, with no predictions about how they will fare in the regulatory process.

		1 New Date for Vandetanib The FDA is continuing its review of vandetanib (Zictifa), a tyrosine kinase inhibitor intended for the treatment of patients with unresectable locally advanced or metastatic medullary thyroid cancer. AstraZeneca said the agency extended its decision date from January 7 to April 7 in order to review a proposed risk evaluation and mitigation strategy the company was required to submit as part of the process.

		Ipilimumab Decision Anticipated The FDA’s impending decision on Bristol-Myers Squibb’s promising new melanoma drug ipilimumab (Yervoy) remains a matter of great anticipation in clinical and industry circles. The agency had postponed a decision on the drug until March 26 in order to review additional information it had requested, the company announced in November. The FDA’s Oncologic Drugs Advisory Committee was scheduled to consider the drug at a February 9 meeting, but the meeting was canceled because the agency said it had resolved the scientific issues the panel was supposed to consider.

		More Indications Sought for Fusilev A ready-to-use formulation of Fusilev (levoleucovorin) for injection would be available to treat patients with advanced metastatic colorectal cancer if the FDA approves a supplemental new drug application submitted earlier this month. Spectrum Pharmaceuticals anticipates agency action by April 29. Fusilev, now available as freeze-dried powder, is approved as rescue therapy for osteosarcoma patients who have been treated with high doses of methotrexate and to diminish the toxicity of methotrexate. The new formulation does not have to be reconstituted and is of higher strength than the currently approved version, a company official said in a press release.

		Avastin Battle Not Over Yet Genentech Inc is asking the FDA for a hearing on the agency’s plans to disallow the metastatic breast cancer indication on the label for Avastin (bevacizumab). The company, a member of the Roche Group, said patients have been relying 8 / 01.11 upon the drug for 2 years, and that the European Medicines Agency reached a different conclusion than the FDA after examining the same data. Genentech filed a detailed response on January 18. In December, the FDA said the breast cancer indication should be removed because studies showed the overall survival and disease progression benefits do not outweigh serious adverse effects. The label indication for metastic HER2-negative breast cancer remains in place during the appeal. Avastin gained accelerated approval as a breast cancer treatment in 2008. Since 2004, Avastin has been approved for patients with colorectal cancer, non- small cell lung cancer, glioblastoma, and renal cell carcinoma.

		Iniparib Staying on Fast Track Sanofi-aventis intends to file regulatory submissions within the next several months for iniparib (BSI- 201), a PARP inhibitor that has been on the FDA’s fast track as a treatment for women with metastatic triple-negative breast cancer (mTNBC). The company reported final phase II data earlier this month, saying submissions are planned in the United States during the first quarter and with the European Union later this year. The drug is in phase III trials for mTNBC and squamous non-small cell lung cancer, and phase II trials for ovarian, uterine, and brain cancers. Sanofi-aventis research center in Strasbourg, France.

		Lymphoma Drug Application in the Works Key findings from a phase II clinical trial of brentuximab vedotin (SGN-35) for patients with relapsed or refractory systemic anaplastic large cell lymphoma generated excitement in research circles in December. Seattle Genetics, Inc said it plans to submit a biologics license application to the FDA during the first quarter this year. Millennium: The Takeda Oncology Company, which is developing the drug in a collaboration with Seattle Genetics, has started similar discussions with the European Medicines Agency.

		Progress Reported on Blood Cancer Drug The oral drug INCB18424 demonstrated positive results in a pivotal phase III clinical trial for the treatment of myelofibrosis, a blood cancer that compromises bone marrow, the Incyte Corporation said earlier this month. The company said plans are in the works to submit a new drug application to the FDA by July. The drug, which works by inhibiting JAK enzymes, is being developed under a special protocol assessment designed to expedite the approval process.

	FDA Updates New Drug for Cancer Pain Approved Abstral (fentanyl), an opioid analgesic administered in fast-acting transmucosal tablets, has been approved for cancer patients aged ≥18 who already use opioid pain medication around the clock and are experiencing periodic breakthrough pain. The FDA, in its January 7 approval notice, said the drug will be available only through healthcare professionals and pharmacies registered in the agency’s risk evaluation and mitigation strategy (REMS) program. The ProStrakan Group plc expects to launch Abstral by April, according to Orexo, a Swedish company partnering with ProStrakan. http://hcp.lv/ib5Eeu

	Gardasil Approved to Prevent Anal Cancer The list of ways in which Gardasil can be used to battle the human papillomavirus (HPV) grew in December with the FDA’s approval of the vaccine as a means of preventing anal cancer and precancerous lesions due to HPV in people aged 9 through 26. The vaccine was found to be 78% effective in a randomized, controlled trial of men who self-identified as having sex with men, the agency said in its December 22 approval announcement. Gardasil, a Merck & Co, Inc product initially approved in 2006, is indicated for the prevention of cervical, vulvar, and vaginal cancer, as well as precancerous HPV-related lesions in women. It also is approved for the prevention of genital warts caused by 2 HPV strains in men and women. http://hcp.lv/fhSXNx

	3 Oncology Diagnostic Devices Gain Support The Center for Devices and Radiological Health has approved a test that can measure overexpression of the HER2 gene, a mammography system, and an enhanced bladder cancer diagnostic method.

	HER2 FISH pharmDxTM employs a fluorescent in situ hybridization (FISH) method to determine whether too many copies of the HER2 gene are present in gastric cancer patients who are under consideration for treatment with trastuzumab (Herceptin). Dako Denmark A/S is bringing the test to market. http://hcp.lv/gtSR6z 

	The KODAK DirectView CR Mammography System consists of a cassette that fits into standard KODAK mammography x-ray equipment and converts latent images captured by laser scanning into final digital images that it then processes for analysis and archiving. Carestream Health, Inc developed the product. http://hcp.lv/g3uY3V 

	The Karl Storz Photodynamic Diagnostic D-Light C (PDD) System is designed to improve the detection of nonmuscle invasive papillary cancer of the bladder. The system, which transmits blue light through a fluid cable connected to an endoscope, functions as an optional add-on to be used in combination with the diagnostic imaging drug Cysview,® according to the FDA. Developed by Karl Storz Endoscopy-America, Inc, the system includes a light source, cable, cystoscopes, and a camera. http://hcp.lv/gfYFZG 10 / 01.11

	Web Resources Getting Up to Speed on Information Technology If you want to keep track of the federal government’s push to expand health information technology, check out the updates that David Blumenthal, MD, MPP, posts on the US Department of Health and Human Services’ Website. Blumenthal, national coordinator for health information technology, summarized 4 major programs now underway in a December 10 posting that links to more detailed reports on each area. It has been nearly 2 years since the Health Information Technology for Economic and Clinical Health (HITECH) Act was signed into law. http://hcp.lv/esLfbl

	NCCN Expanding Patient-Friendly Materials The National Comprehensive Cancer Network (NCCN) is rapidly building its library of guideline materials developed specifically with patients, their loved ones, and caregivers in mind. The NCCN Guidelines for PatientsTM series debuted in September with consumer-friendly versions of the breast and lung cancer guidelines that form the standard of care for oncology professionals. The list of booklets has now been expanded to separate guides for melanoma, multiple myeloma, ovarian cancer, and prostate cancer. The organization plans to publish patient versions of guidelines for all major adult cancer sites eventually. http://hcp.lv/gLyYaZ

	Taking a Bow Meeting the Gold Standard CEO Cancer Gold StandardTM accreditation, which recognizes corporate efforts to battle cancer in workplaces, was conferred upon 6 companies and institutions in December. Those awarded the designation initiated programs to promote healthy lifestyle choices among employees and their families, as well as access to quality care and clinical trials once a cancer diagnosis is made. The CEO Roundtable on Cancer is a 10-year-old organization that has established a process where companies are required to meet cancer-fighting standards to receive the accreditation. Honored were: Dell Inc, Round Rock, Texas; Avera McKennan Hospital and University Health Center, Sioux Falls, South Dakota; Cancer Prevention and Research Institute of Texas, Austin; Logistics Health, Inc, La Crosse, Wisconsin; United Health Services Hospitals, Binghamton, New York; and Vassar Brothers Medical Center, Poughkeepsie, New York. www.cancergoldstandard.org onclive.com Check Up

	In the News Chronic Disease Patients Embrace Health-Related Social Networking People living with chronic diseases, including cancer, are far less likely than healthy adults to spend time on the Internet. But when they do venture online, these patients are particularly likely to get involved with blogging and online health discussions. Those were among the insights in the Cancer 2.0: A Summary of Recent Research that the Pew Research Center published in December. The Washington, DC-based foundation drew from a variety of studies to paint a picture of the ways in which cancer patients use the Internet. In general, cancer patients are skeptical of getting information about their disease from Internet sources. A National Cancer Institute survey found that the public’s “trust in information from healthcare professionals had increased while their trust in health information from the Internet had waned” between 2002 and 2008, according to the Pew report. Overall, 81% of healthy adults report going online while a comparatively lower 62% of people living with 1 or more chronic diseases report doing so, the Pew study said. Regardless of their health status, though, 8 of 10 Internet users look for health information. And, the Internet is a potent force for cancer patients. The report said social networking activities are attractive to people living with chronic diseases and offers suggestions for ways in which healthcare providers can guide discussions. “The online conversation cannot be controlled, but trusted sources can contribute by making it easy for Internet users to find and share up-to-date information,” the researchers said. “For example, instead of publishing only in PDF, organizations can publish in a way that allows someone to grab a chart, a data point, or an image and link back to specific part of a document. Publicly available data sets can also be posted in computable formats.” To read the full report, visit http://hcp.lv/hgRC9u

	Need a Reason to Improve Your Health? There’s Evidence for These Resolutions It’s not too late to make New Year’s resolutions and, if you need an excuse to put healthy lifestyle choices on your list, the University of Buffalo (UB) has advice from the experts. The school, part of the State University of New York system, has 10 research-based resolutions posted on its Website—along with the studies conducted by university researchers that back up the suggestions. UB researchers found that eating more soy products may reduce the risk of developing breast cancer, getting 7 hours of sleep might decrease the risk of developing diabetes, and paying cash at the grocery store might lead to fewer junk food purchases. www.buffalo.edu/news/12128 12 / 01.11 Source: Fox S, Purcell K; Pew Research Center. Chronic disease and the Internet. www.pewinternet.org/Reports/2010/Chronic-Disease.aspx. Published March 24,2010. Accessed January 18, 2011.

	Americans Are Buying Prescription Drugs From Rogue Online Pharmacies in Droves More Americans are turning to illegal Internet pharmacies to purchase prescription drugs, according to a new survey by the Partnership at Drugfree.org. The survey found that 36 million patients, or 1 in 6 adults, purchased medications online without a prescription. The new data were released in December at the White House Intellectual Property Health and Safety Forum. The survey was funded by the Alliance for Safe Online Pharmacies (ASOP), whose members include the American Pharmacists Association and the National Association of Chain Drug Stores. According to ASOP, more than 95% of Internet organic search results lead patients to rogue online sellers peddling unapproved and potentially counterfeit medicine—without a prescription. Experts say more must be done to educate patients about the dangers of patronizing these fraudulent businesses. “Consumers need to understand that the products they receive from Internet drug sellers are often not the same, FDA-approved medicine that they could get from a legitimate pharmacy. Products sold on rogue Web sites may be ineffective, harmful, or worse,” said Libby Baney, an advisor to ASOP. To curb the practice, ASOP is partnering with a voluntary task force of 11 major Internet commerce companies, including American Express, Microsoft, Google, PayPal, and Yahoo!. The newly formed nonprofit group aims to shut down rogue sites and provide patients with legitimate channels for buying drugs online. 

	HCPLive Highlights Intellisphere, the parent company of Oncology Net Guide and a family of medical publications, offers a wealth of news and information for oncology and other healthcare professionals on its Website, www. HCPLive.com. Here are a few highlights: Scenes From the Radiology Archives Care to share an interesting echocardiography video? Echojournal, an online ultrasound video sharing site, is available round- the-clock through the HCPLive Network. Registered users are invited to upload and discuss videos (edited, of course, to protect the privacy of patients). One recent addition, for example, depicts the coarctation of the aorta, complete with sound. The site offers complete social networking functions, including the ability to make friends, follow the video feeds of individuals or departments, and join in discussions. The site is intended for current and future physicians and healthcare professionals who use echocardiography in their practices. http://hcp.lv/eQOM0x Pharmacy Times Puts Focus on Helping Patients With Venous Thromboembolism The risks that cancer patients face from venous thromboembolism (VTE) has been a widely studied aspect of oncology care. Pharmacy Times is offering a free, online refresher course on managing VTE called “Venous Thromboembolism and Cancer: An Opportunity for Pharmacists to Optimize Care.” Rowena N. Schwartz, PharmD, BCOP, director of Oncology Pharmacy, The Johns Hopkins Hospital, Baltimore, Maryland, developed the VTE course as a continuing medical education program for pharmacists, and any healthcare professional with an interest in the subject would benefit from the overview. The course includes several case studies. http://hcp.lv/hu5Jfu Webinars Offer Tips for Physicians on Practical Uses of Technology If you’d like to listen to experts on a variety of technology topics, check out the Webinars offered on HCPLive. One popular entry is a discussion by Don S. Dizon, MD, FACP, an early iPad adopter and HCPLive blogger, about the benefits of using the iPad and apps that are particularly useful for healthcare professionals. Other topics include a debate about small versus large vendors for electronic health records and integrated marketing planning both online and offline. The content is free to registered users—and registration is also free! For details, visit www.hcplive.com/webinars.

From tiny biotech firms to giant pharmaceutical companies, the oncology drug development pipeline is pulsing with activity.

OncLive

Articles

Net Guides: Colon Cancer

Nanotechnology X-ray Method Aims to Kill Cancer But Spare Healthy Tissue

2011 Gastrointestinal Cancers Symposium

7 in 2011: A Short List of Drugs to Watch